Associated tags: Almirall, ALM, Patient, Health, Pharmaceutical, Biotechnology, BME, Dermatology, Pharmaceutical industry, Adherence, Eli Lilly and Company, Adolescence, AD, Safety, Advocate, Disease, Human, Other Health, TCS, Clinical Trials
Locations: EUROPEAN UNION, WASHINGTON, EC, AE, SPAIN, EUROPE
Retrieved on:
Monday, February 19, 2024
Health,
Other Science,
Research,
Pharmaceutical,
Science,
Biotechnology,
BME,
Dermatology,
Novo Nordisk,
ALM,
Multimedia,
Patient,
Partnership,
Vaccine Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, announced today that it has entered into an exclusive license agreement with Novo Nordisk for rights to the IL-21 blocking monoclonal antibody NN-8828.
Key Points:
- Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, announced today that it has entered into an exclusive license agreement with Novo Nordisk for rights to the IL-21 blocking monoclonal antibody NN-8828.
- Under the agreement, Almirall obtains global rights to develop and commercialize this monoclonal antibody in certain fields, including immune inflammatory dermatological diseases.
- Novo Nordisk will receive an upfront payment as well as additional development and commercial milestone payments and tiered royalties based upon future global sales.
- NN-8828 is a first-in-class in dermatology, high affinity monoclonal antibody that targets the cytokine IL-21 and has been developed by Novo Nordisk up to Phase ll in non-dermatological indications.
Retrieved on:
Friday, November 17, 2023
Health,
Other Health,
Other Science,
General Health,
Science,
Pharmaceutical,
Biotechnology,
Allergic conjunctivitis,
Itch,
Adolescence,
ALM,
Adherence,
Safety,
Hope,
European Commission,
Advocate,
Disease,
Teaching hospital,
Civil service commission,
TCS,
Patient,
Week,
Doctor of Philosophy,
Conjunctivitis,
Atopic dermatitis,
BME,
Eli Lilly and Company,
MD,
Skin,
Almirall,
Human,
Pharmaceutical industry,
Vaccine,
Dermatology “The arrival of novel biologic treatments is marking a new paradigm in the management of atopic dermatitis.
Key Points:
- “The arrival of novel biologic treatments is marking a new paradigm in the management of atopic dermatitis.
- The approval of lebrikizumab represents a leap forward in our ability to provide patients with an effective therapeutic option with demonstrated safety profile.
- Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including atopic dermatitis, in Europe.
- Almirall expects regulatory decisions for lebrikizumab in moderate-to-severe atopic dermatitis in additional European markets, including the United Kingdom and Switzerland.
Retrieved on:
Tuesday, November 14, 2023
Biotechnology,
Pharmaceutical,
Health,
ALM,
Skin,
CSO,
Patient,
De novo,
Therapy,
BME,
Drug discovery,
Partnership,
R,
Almirall,
Medical device,
AI Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI ), a generative AI drug creation company, today announced a drug discovery partnership aimed to develop and commercialize AI-designed therapeutics to fight chronic and debilitating dermatological diseases.
Key Points:
- Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI ), a generative AI drug creation company, today announced a drug discovery partnership aimed to develop and commercialize AI-designed therapeutics to fight chronic and debilitating dermatological diseases.
- The partnership combines Absci’s Integrated Drug Creation™ platform with Almirall’s dermatological expertise with the goal of delivering life-changing medicines to patients, marking another step forward in AI drug creation.
- The partnership represents Almirall’s first de novo AI drug collaboration, and it comes only months after Absci announced it could design and validate de novo therapeutic antibodies using its ‘zero-shot’ generative AI.
- Under the terms of the partnership, Absci will apply its de novo generative AI technology to create and commercialize therapeutic candidates for two dermatological targets.
Retrieved on:
Thursday, November 9, 2023
Almirall finished the first 9 months of 2023 with a favourable balance sheet and solid liquidity position at 0.2x Net Debt to EBITDA.
Key Points:
- Almirall finished the first 9 months of 2023 with a favourable balance sheet and solid liquidity position at 0.2x Net Debt to EBITDA.
- “Almirall has delivered a consistently strong operational performance throughout the first nine months of 2023, and we are pleased to modestly upgrade our Net Sales guidance for the year.
- Almirall expects Q4 to resume growth momentum and anticipates that the absolute growth for 2023 will be comparable to that of 2022.
- In addition, Almirall expects to initiate a phase I clinical study for IL-2muFc autoimmune drug candidate around the end of 2023.
Biotechnology,
General Health,
Other Health,
Health,
Pharmaceutical,
Almirall,
Lilly,
Eli Lilly and Company,
AD,
Aes,
Eli Lilly,
Adherence,
Conference,
Maintenance,
Addiction severity index,
Conditional sentence,
IGA,
Shingles,
Abstract,
The New England Journal of Medicine,
Conjunctivitis,
British Journal of Dermatology,
Atopic dermatitis,
Patient,
Pharmaceutical industry,
Dermatology,
Tree-adjoining grammar,
EASI In ADjoin, 62 percent of patients reported adverse events (AEs), most of which were mild or moderate in severity.
Key Points:
- In ADjoin, 62 percent of patients reported adverse events (AEs), most of which were mild or moderate in severity.
- The most common side effects of lebrikizumab were conjunctivitis, injection site reactions and shingles (herpes zoster).
- “Results from ADjoin reinforce the strong efficacy and safety profile of lebrikizumab seen in the other Phase 3 atopic dermatitis trials.
- Lilly has exclusive rights for development and commercialization of lebrikizumab in the U.S. and the rest of the world outside Europe.
Health,
Managed Care,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Congress,
EudraCT,
Eli Lilly and Company,
Knowledge,
European Academies' Science Advisory Council,
Advantage,
CHMP,
Abstract,
Advocate,
Ciclosporin,
United Kingdom,
BME,
University,
Week,
Safety,
ALM,
Human,
Disease,
NRS,
Psoriasis Area and Severity Index,
Journal of the European Academy of Dermatology and Venereology,
Almirall,
Adolescence,
Marketing,
IGA,
Adherence,
AD,
TCS,
News,
Overalls,
EASI,
Patient,
Quality of life,
Pharmaceutical industry,
Dermatology,
Venereology Improvements in absolute skin response over 16 weeks for patients with moderate-to-severe AD treated with lebrikizumab or placebo were also shared.
Key Points:
- Improvements in absolute skin response over 16 weeks for patients with moderate-to-severe AD treated with lebrikizumab or placebo were also shared.
- Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including AD, in Europe.
- Almirall expects regulatory decisions for lebrikizumab in moderate-to-severe AD in additional European markets, including the United Kingdom and Switzerland in 2024.
- † More information about the Phase 3 studies: ADvocate 1: EudraCT Number 2019-002932-10; NCT04146363; ADvocate 2: EudraCT Number 2019-002933-12; NCT04178967; ADhere: EudraCT Number 2019-004300-34; NCT04250337
Retrieved on:
Tuesday, October 10, 2023
Health,
Clinical Trials,
Research,
Pharmaceutical,
Science,
Biotechnology,
Partnership,
Art,
Multimedia,
Knowledge,
BME,
Industrial microbiology,
ALM,
Sant Feliu,
Almirall,
Telekom Innovation Laboratories,
University,
Patient,
Fine chemical,
Management,
Sant Feliu de Llobregat The center serves as a hub where researchers from biotech companies, startups, universities, and other scientific institutions can collaborate fostering an ideal environment for innovation.
Key Points:
- The center serves as a hub where researchers from biotech companies, startups, universities, and other scientific institutions can collaborate fostering an ideal environment for innovation.
- The establishment of an Innovation Laboratory at Almirall's R&D facilities is a strategic milestone for Centrient.
- Rex Clements, Chief Executive Officer of Centrient Pharmaceuticals, expressed his enthusiasm, stating: "The new Innovation Laboratory is an exhilarating strategic leap for Centrient Pharmaceuticals.
- Almirall's ultimate goal is to create a pharmaceutical innovation hub where different companies can execute their innovation strategies.
Retrieved on:
Friday, September 15, 2023
Biotechnology,
Other Health,
Health,
Pharmaceutical,
Clinical Trials,
Trinity College,
Maintenance,
Eczema Area and Severity Index,
Disease,
Civil service commission,
AE,
Week,
Dermatitis,
European Medicines Agency,
Adherence,
Committee for Medicinal Products for Human Use,
Quality of life,
Atopic dermatitis,
Almirall,
TCS,
Committee,
EMA,
Trinity College Dublin,
BME,
Advocate,
ALM,
Patient,
European,
Adolescence,
United Kingdom,
Eli Lilly and Company,
Itch,
Hospital,
AD,
EudraCT,
Conjunctivitis,
EC,
Human,
Skin,
European Commission,
Safety,
CHMP,
Vaccine,
Pharmaceutical industry,
Dermatology The positive CHMP opinion is now being reviewed by the European Commission (EC).
Key Points:
- The positive CHMP opinion is now being reviewed by the European Commission (EC).
- “Atopic dermatitis, commonly known as atopic eczema, can have a profound impact on the quality of life for those it affects.
- "The positive CHMP recommendation for EBGLYSS in moderate to severe AD represents a significant milestone in bringing a next-generation biologic therapy to people living with atopic dermatitis, providing a much needed additional treatment option.
- Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including atopic dermatitis, in Europe.
Biotechnology,
Pharmaceutical,
Health,
BNP PARIBAS,
European Parliament,
European,
SEC Rule 144A,
Annual,
Sociedad, Morazán,
Equity carve-out,
ABB,
Prospectus,
ALM,
European Economic Area,
Council,
BNP,
Joint,
Grupo Aval,
CNMV,
Gallardo,
J. P. Morgan,
Annual general meeting,
Security (finance),
EU,
Regulation Books will be open from now and are expected to close no later than 08:00 a.m.
Key Points:
- Books will be open from now and are expected to close no later than 08:00 a.m.
- on 13 June 2023, when final results of the ABB Process will be published to the market.
- The Gallardo family, holding indirectly approximately 59.66% of the share capital of the Company, has undertaken to participate in the Capital Increase via Grupo Plafín, S.A.U.
- will be subject to a lock-up undertaking of 180 days from the closing of the Capital Increase, subject to market standard exceptions.
Intellectual property law,
Law,
Patent law,
Business law,
Intangible assets,
Expense,
Royalty payment,
Thermi,
License,
Ownership,
Intellectual property,
Economy Under the settlement, Viveve will receive a monetary consideration and on-going royalties.
Key Points:
- Under the settlement, Viveve will receive a monetary consideration and on-going royalties.
- Thermi will receive non-exclusive licenses to Viveve IP as well as other mutual agreements relating to certain intellectual property owned by the companies.
- "We are pleased to come to a mutual agreement with Viveve and conclude this matter," said Vladimir Paul-Blanc, President and General Manager of Thermi.
- Founded in 2012, Thermi is a U.S.-based company with its headquarters in Irving, Texas and R&D in Boston, MA.
